Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster

Vaccine

Volumn 28, Issue 25, 2010, Pages 4204-4209

  Mills, Richard ^a   Tyring, Stephen K ^b   Levin, Myron J ^c   Parrino, Janie ^d   Li, Xiaoming ^d   Coll, Kathleen E ^d   Stek, Jon E ^d   Schlienger, Katia ^d   Chan, Ivan S F ^d   Silber, Jeffrey L ^d  

^a Palmetto Medical Research   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

gpELISA; Herpes zoster; Immunogenicity; Safety; Zoster vaccine

Indexed keywords

HERPES ZOSTER IMMUNOGLOBULIN; PLACEBO; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; KAPOSI VARICELLIFORM ERUPTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TACHYCARDIA; VACCINATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; UNITED STATES;

EID: 77952582971     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.003     Document Type: Article

References (17)

1. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract 25 (1975) 571-575
2. Gnann Jr. J.W., and Whitley R.J. Herpes zoster. N Engl J Med 347 (2002) 340-346
3. ZOSTAVAX® (zoster vaccine, live) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2007. Available from: http://www.fda.gov/Cber/label/zostavaxLB.pdf [accessed 27.03.09].
4. ® Product Approval Information. Available from: http://www.fda.gov/cber/products/zostavax.htm [accessed 07.05.09].
5. EMEA Committee for Medical Products for Human Use: March 2006 Monthly Report. Available from: http://www.emea.europa.eu/pdfs/human/press/pr/10293706en.pdf [accessed 12.12.06].
6. Recommendations of the Advisory Committee on Immunization Practices. Centers for Disease Control, Prevention of herpes zoster. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm?s_cid=rr5705a1_e [accessed 20.08.08].
7. Centers for Disease Control. National Immunization Program, Adult Immunization Schedule. Available from: http://www.cdc.gov/nip/recs/adult-schedule.htm [accessed 27.11.06].
8. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
9. Levin M.J., Oxman M.N., Zhang J.H., Johnson G.R., Stanley H., Hayward A.R., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197 (2008) 825-835
10. Hammond O., Wang Y., Green T., Antonello J., Kuhn R., Motley C., et al. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 78 (2006) 1679-1687
11. Long CE, Kouides RW, Peer S, LaForce FM, Whitney C, Bennett NM. Accuracy of self-report of pneumococcal vaccine status in older adults. Abstracts of the 127th American Public Health Association Meeting, November 7-11, 1999. Chicago, Illinois: American Public Health Association, 1999. p. 124.
12. St Sauver J.L., Hagen P.T., Cha S.S., Bagniewski S.M., Mandrekar J.N., Curoe A.M., et al. Agreement between patient reports of cardiovascular disease and patient medical records. Mayo Clin Proc 80 (2005) 203-210
13. Tango T. Equivalence test and confidence intervals for the difference in proportions for the paired-sample design. Statis Med 17 (1998) 891-908
14. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130
15. ®. Clin Vaccine Immunol 15 (2008) 314-319
16. Kerzner B., Murray A.V., Cheng E., Ifle R., Harvey P.R., Tomlinson M., et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 55 (2007) 1499-1507
17. Sutradhar S.C., Wang W.W.B., Schlienger K., Stek J.E., Xu J., Chan I.S.F., et al. Comparison of the levels of immunogenicity and safety of ZOSTAVAX in adults 50 to 59 years old and in adults 60 years old or older. 16 (2009) 646-652